Loading company
Rein Therapeutics, Inc.
RNTX · Nasdaq · ·
$0.79+8.7%Sep 29 close
- 1M
- +4.1%
- 6M
- -37.5%
- 1Y
- -30.7%
- 5Y
- -96.3%
RNTX · Nasdaq · ·
$0.79+8.7%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$6.4M | -$6.8M | +6.55% |
| Profit per share | -$0.10 | -$0.28 | +64.29% |
| Free Cash Flow | -$6.3M | -$4.7M | -33.40% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Rein Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Reins lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis was initiated in May 2025. Reins second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rein Therapeutics, Inc.’s Item 2.02 8-K filed May 15, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.